[1]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,(04):104-106.[doi:10.3969/j.issn.1006-1959.2019.04.033]
 HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Medical Information,2019,(04):104-106.[doi:10.3969/j.issn.1006-1959.2019.04.033]
点击复制

Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年04期
页码:
104-106
栏目:
临床研究
出版日期:
2019-02-15

文章信息/Info

Title:
Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer
文章编号:
1006-1959(2019)04-0104-03
作者:
黄 雨1楼浩男2涂 刚1
(重庆医科大学附属第一医院内分泌乳腺外科1,血管外科2,重庆 400016)
Author(s):
HUANG Yu1LOU Hao-nan2TU Gang1
(Department of Endocrine and Breast Surgery1,Department of Vascular Surgery2,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
乳腺肿瘤Luminal B新辅助化疗病理完全缓解影响因素
Keywords:
Breast neoplasms Luminal BNeoadjuvant chemotherapyPathological complete remission Influencing factors
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2019.04.033
文献标志码:
A
摘要:
目的 探讨Luminal B型乳腺癌TEC新辅助化疗的疗效及其影响因素。方法 对2016年1月~2018年6月于我院行4次TEC方案新辅助化疗的81例Luminal B型乳腺癌患者的临床病历资料进行回顾性分析,分析临床病理特征及相关指标的改变与疗效的相关性。结果 4周期新辅助化疗pCR率为4.94%,临床疗效与临床分期存在统计学意义(P<0.05),是否获得pCR与年龄、BMI、绝经状态、原发肿瘤大小、肿瘤部位、确诊时淋巴结状态、PR、P53、Ki67均无统计学意义(P>0.05)。而除去4例获得pCR的患者,剩余77例乳腺癌患者新辅助化疗前后ER、PR的表达状态、Ki67指数的差异具有统计学意义(P<0.05)。结论 临床分期晚的患者新辅助化疗疗效相对较差,Ki67可能是乳腺癌新辅助化疗疗效的预测指标。
Abstract:
Objective To investigate the efficacy and influencing factors of neoadjuvant chemotherapy for Luminal B breast cancer. Methods The clinical medical records of 81 patients with Luminal B breast cancer who underwent 4 TEC regimen neoadjuvant chemotherapy in our hospital from January 2016 to June 2018 were retrospectively analyzed. The clinicopathological features and related indicators were analyzed. Correlation of efficacy. Results The pCR rate of neoadjuvant chemotherapy was 4.94%. The clinical efficacy and clinical stage were statistically significant (P<0.05). Whether pCR and age, BMI, menopausal status, primary tumor size, tumor location, and lymph node status at diagnosis were obtained. There were no significant differences in PR, P53 and Ki67 (P>0.05). Except for 4 patients with pCR, the expression of ER and PR and the Ki67 index of 77 patients with breast cancer before and after neoadjuvant chemotherapy were statistically significant (P<0.05). Conclusion Neoadjuvant chemotherapy is relatively ineffective in patients with late clinical stage. Ki67 may be a predictor of neoadjuvant chemotherapy for breast cancer.

参考文献/References:


[1]Jeruss JS,Mittendorf EA,Tucker SL,et al.Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy[J].J Clin Oncol,2008,26(2):246-252.
[2]Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008,26(8):1275-1281.
[3]Cortazar P,Zhang L,Untch M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis[J].Lancet,2014,384(9938):164-172.
[4]Wu K,Yang Q,Liu Y,et al.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy[J].World Journal of Surgical Oncology,2014(12):95.
[5]Yu Y,Xiang H,He XM,et al.Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer-a single center experience[J].Asian Pac J Cancer Prev,2013,14(4):2401-2406.
[6]梁文举,王勤,刘莹,等.过表达α 2,3-唾液酸转移酶基因对乳腺癌MDA-MB-231细胞侵袭能力的影响[J].中国临床药理学杂志,2017,33(20):2039-2042.
[7]巩福玉.Ki67在乳腺癌新辅助化疗中的疗效评价及预测价值[D].安徽医科大学,2014.

相似文献/References:

[1]张世玉,刘汉成,张宏旭,等.早期乳腺癌患者血清中VEGF-C与前哨淋巴结状态的相关性研究[J].医学信息,2018,(02):71.[doi:10.3969/j.issn.1006-1959.2018.02.024]
 ZHANG Shi-yu,LIU Han-cheng,ZHANG Hong-xu,et al.Correlation between Serum VEGF-C and Sentinel Lymph Node Status in Patients with Early Stage Breast Cancer[J].Medical Information,2018,(04):71.[doi:10.3969/j.issn.1006-1959.2018.02.024]
[2]李 科.骨形态发生蛋白4与乳腺癌骨转移的相关性研究[J].医学信息,2018,(13):17.[doi:10.3969/j.issn.1006-1959.2018.13.005]
 LI Ke.Relationship between Bone Morphogenetic Protein 4 and Bone Metastasis in Breast Cancer[J].Medical Information,2018,(04):17.[doi:10.3969/j.issn.1006-1959.2018.13.005]

更新日期/Last Update: 2019-03-07